Immunotherapy drug shows promise for tough bladder cancer cases
NCT ID NCT02625961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or with another agent in 296 people with high-risk non-muscle-invasive bladder cancer that did not respond to standard BCG therapy. Participants received the drug intravenously every three weeks. The goal was to see if the treatment could shrink tumors or prevent the cancer from coming back, offering an alternative to bladder removal surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) alone or with vibostolimab
What this could lead to
If successful, this could offer a new treatment option for people with bladder cancer that hasn't responded to standard therapy, potentially avoiding bladder removal surgery.
What could go wrong
This is a phase II trial, so results are still early. The drug may not work for everyone, and side effects like immune-related reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.